UB Paderborn / Katalog / Suche / in CDI

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

Oncogene, 2010-08, Vol.29 (32), p.4517-4527

2010

Link zum Volltext

Verfügbarkeit prüfen

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation

Leukemia, 2009-09, Vol.23 (9), p.1634-1642

2009

Link zum Volltext

Verfügbarkeit prüfen

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

Cell death & disease, 2010-08, Vol.1 (8), p.e68-e68

2010

Link zum Volltext

Verfügbarkeit prüfen

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2 HER2 peptide-based vaccination construct

British journal of cancer, 2005-04, Vol.92 (8), p.1421-1429

2005

Link zum Volltext

Verfügbarkeit prüfen

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

Cell death and differentiation, 2006-04, Vol.13 (4), p.576-585

2006

Link zum Volltext

Verfügbarkeit prüfen

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

Oncoimmunology, 2022-12, Vol.11 (1), p.2127508-2127508

2022

Link zum Volltext

Verfügbarkeit prüfen

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells

Cell death and differentiation, 2007-09, Vol.14 (9), p.1678-1687

2007

Link zum Volltext

Verfügbarkeit prüfen

A universal strategy for stable intracellular antibodies

Journal of immunological methods, 2005-08, Vol.303 (1), p.19-39

2005

Link zum Volltext

Verfügbarkeit prüfen

A Novel Bispecific Tetravalent Antibody Fusion Protein to Target Costimulatory Activity for T-cell Activation to Tumor Cells Overexpressing ErbB2/HER2

Journal of molecular biology, 2005-03, Vol.346 (5), p.1299-1311

2005

Link zum Volltext

Verfügbarkeit prüfen

P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii47-ii47

2023

Link zum Volltext

Verfügbarkeit prüfen

P06.06.B PD-1 CHECKPOINT INHIBITION IN CONJUNCTION WITH NK-92/5.28.Z CELLS IS EFFECTIVE IN AN ADVANCED-STAGE GLIOBLASTOMA MOUSE MODEL AND INDUCES A CD4-ENRICHED T CELL RESPONSE

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii46-ii46

2023

Link zum Volltext

Verfügbarkeit prüfen

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.411-423

2008

Link zum Volltext

Verfügbarkeit prüfen

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii15-ii15

2021

Link zum Volltext

Verfügbarkeit prüfen

P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii60-iii60

2019

Link zum Volltext

Verfügbarkeit prüfen

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii283-iii283

2018

Link zum Volltext

Verfügbarkeit prüfen

P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

Journal for immunotherapy of cancer, 2020-10, Vol.8 (Suppl 2), p.A47-A47

2020

Link zum Volltext

Verfügbarkeit prüfen

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv24-iv25

2016

Link zum Volltext

Verfügbarkeit prüfen

P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii51-iii52

2017

Link zum Volltext

Verfügbarkeit prüfen

P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Journal for immunotherapy of cancer, 2020-10, Vol.8 (Suppl 2), p.A46-A47

2020

Link zum Volltext

Verfügbarkeit prüfen

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Nuclear medicine and biology, 2008-07, Vol.35 (5), p.579-588

2008

Link zum Volltext

Verfügbarkeit prüfen

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii13-ii13

2014

Link zum Volltext

Verfügbarkeit prüfen

ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii44-iii44

2014

Link zum Volltext

Verfügbarkeit prüfen

A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells

Journal of immunological methods, 2007-08, Vol.325 (1), p.140-147

2007

Link zum Volltext

Verfügbarkeit prüfen

Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery

The FEBS journal, 2005-08, Vol.272 (16), p.4221-4236

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Breast cancer research : BCR, 2005-01, Vol.7 (5), p.R617-R626, Article R617

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2 HER2 peptide-based vaccination construct

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells

A universal strategy for stable intracellular antibodies

A Novel Bispecific Tetravalent Antibody Fusion Protein to Target Costimulatory Activity for T-cell Activation to Tumor Cells Overexpressing ErbB2/HER2

P06.10.A CAR-ENGINEERED PRIMARY NK CELLS SHOW PROMISING EFFECTS AS TARGETED THERAPY AGAINST EGFR-POSITIVE GLIOBLASTOMA

P06.06.B PD-1 CHECKPOINT INHIBITION IN CONJUNCTION WITH NK-92/5.28.Z CELLS IS EFFECTIVE IN AN ADVANCED-STAGE GLIOBLASTOMA MOUSE MODEL AND INDUCES A CD4-ENRICHED T CELL RESPONSE

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells

Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Suchergebnisse filtern